Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 430Neoplasms, Plasma Cell 58Recurrence 33Smoldering Multiple Myeloma 17Neoplasms 14Hematologic Diseases 11Immunoglobulin Light-chain Amyloidosis 8Leukemia, Plasma Cell 7Paraproteinemias 6Hematologic Neoplasms 6Amyloidosis 6Neoplasm, Residual 5Renal Insufficiency 4Plasmacytoma 4Lymphoma 4Disease Progression 4Disease 4Blood Protein Disorders 4Lymphoma, Non-Hodgkin 3POEMS Syndrome 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Corneal Diseases 2Bone Marrow Neoplasms 2Wilms Tumor 1Vitamin D Deficiency 1Vascular Diseases 1

Interventions

Tacrolimus 4Epoetin Alfa 4Busulfan 4fludarabine 3Darbepoetin alfa 3Bortezomib 3fludarabine phosphate 2dacetuzumab 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Lenalidomide 2Early Intervention, Educational 2Dexamethasone 2Antilymphocyte Serum 2Alemtuzumab 2venetoclax 1trametinib 1ruxolitinib 1plerixafor 1isatuximab 1ficlatuzumab 1ferrous sulfate 1ferric gluconate 1ethanolamine oleate 1dabrafenib 1Vorinostat 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Lenalidomide × Plasma cell × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡